Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry leaders, the goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities.
Our Carcino3D models offer a platform for in vitro high-throughput, accurate, and rapid drug discovery and screening for novel, combinatorial, and repurposed drugs. Our models can be used for drug efficacy, drug pathways, and toxicity testing. They are bioengineered to de-risk cancer drug testing and pre-clinical trials offering translational data with respect to cancer heterogeneity and microenvironments.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.